The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma
Authors
Keywords
-
Journal
BLOOD
Volume 118, Issue 4, Pages 1052-1061
Publisher
American Society of Hematology
Online
2011-06-01
DOI
10.1182/blood-2011-03-340109
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1
- (2010) Chie Nishioka et al. APOPTOSIS
- High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)
- (2010) Jieru Meng et al. CANCER BIOLOGY & THERAPY
- Blockade of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase and Murine Double Minute Synergistically Induces Apoptosis in Acute Myeloid Leukemia via BH3-Only Proteins Puma and Bim
- (2010) W. Zhang et al. CANCER RESEARCH
- Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
- (2010) Y. N. V. Gopal et al. CANCER RESEARCH
- A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
- (2010) E. B. Haura et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
- (2010) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
- (2010) U. Banerji et al. CLINICAL CANCER RESEARCH
- A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
- (2010) John D. Hainsworth et al. Journal of Thoracic Oncology
- Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
- (2010) Tri K. Nguyen et al. LEUKEMIA RESEARCH
- Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras-Mutated Colorectal Cancer
- (2010) J. J. Tentler et al. MOLECULAR CANCER THERAPEUTICS
- KRASmutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach
- (2010) Young-Kwang Yoon et al. MOLECULAR CARCINOGENESIS
- Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim
- (2010) Jieru Meng et al. PLoS One
- Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
- (2009) R E Board et al. BRITISH JOURNAL OF CANCER
- Extracellular Signal-Regulated Kinase Positively Regulates the Oncogenic Activity of MCT-1 in Diffuse Large B-Cell Lymphoma
- (2009) B. Dai et al. CANCER RESEARCH
- Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95
- (2008) M. A. Park et al. MOLECULAR CANCER THERAPEUTICS
- ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation
- (2008) Jer-Yen Yang et al. NATURE CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now